Wayfinder Biosciences has moved to the second phase of its research collaboration with Daiichi Sankyo after successfully completing the initial phase focused on discovering RNA-targeting small molecules for neurodegeneration. The next phase will develop and optimize these compounds, leveraging Wayfinder's platform to create potent, selective, and orally available drugs. This advancement highlights the potential of Wayfinder's technology to address challenging disease targets. The company also continues to develop an oral small molecule inhibitor for solid tumors.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Peter Schiff, seorang kritikus Bitcoin, menyarankan investor untuk menjual kepemilikan BTC mereka di atas $60.000, memperingatkan potensi kerugian besar. Meskipun Bitcoin baru-baru ini naik 11% di bulan Juli, beberapa analis khawatir bahwa pemulihan ...
